-

Dr. Vince Clinical Research Opens Industry-Leading Clinical Pharmacology Unit

Combines Technology, Expertise and Sustainability to Deliver Smarter, Faster Data

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research (DVCR), today announced the launch of its new, world-class clinical pharmacology unit and headquarters in Overland Park, Kansas. The custom-built, green-inspired research complex was intentionally designed and engineered — with significant investments in infrastructure, research-changing technologies, employee wellness and excellence and environmental sustainability — to be the premier destination in the country for Phase I clinical studies.

Dedicated to Phase I Clinical Trials

“Our vision was to create the top clinical pharmacology unit in the U.S. that enables delivering faster and cleaner data to our biopharmaceutical clients,” said Brad Vince, D.O., a 20-year industry veteran and founder, CEO and medical director. “To accomplish our goals and transform standard industry practices, we built one of the most innovative and technologically advanced Phase I sites ever.”

The company leveraged a robust team of engineers and consultants to plan and construct the new facility and help ensure seamless deployment of the latest technologies for both the physical infrastructure of the 90-bed center and company operations and processes. These key technologies enable the company to deliver higher quality data more efficiently than current industry standards, including:

  • eSource/EDC platform with equipment integration for automated data upload
  • Automated building and inventory management systems
  • Cloud-based environmental monitoring of pharmacy areas
  • Clean lighting technology for killing COVID and other pathogens

Investing in People

The company designed the facility to be one of the world’s most luxurious research centers in order to deliver unrivaled study volunteer recruitment and retention. “However, the facility alone is not enough to create the optimal environment for conducting Phase I trials,” Dr. Vince continued. “The team overseeing a trial is crucial to the execution and success of any clinical study, so we carefully and thoughtfully assembled one of the most experienced early phase leadership teams in the industry so we can provide unparalleled service to our sponsors and positively change the future of clinical research.”

Website: https://sponsors.drvince.com

LinkedIn: https://www.linkedin.com/company/dr-vince-clinical-research/

About Dr. Vince Clinical Research

Dr. Vince Clinical Research (DVCR) is a world-class CRO (contract research organization) with a custom-built, green-designed headquarters and research complex encompassing three buildings in Overland Park, KS. DVCR’s complex includes a 90-bed clinical pharmacology unit featuring a combination of luxurious and private research suites and a GMP-compliant pharmacy with positive and negative pressure compounding rooms. DVCR specializes in conducting clinical trials for both healthy normal volunteers and patient populations in a wide variety of early phase trials. By leveraging both technology and one of the country’s most experienced leadership teams, DVCR provides Smarter, Faster Data™ to its biopharmaceutical clients.

Contacts

Zach Bader
Vice President, Business Development
913-333-3000
zbader@drvince.com

Dr. Vince Clinical Research


Release Summary
Dr. Vince Clinical Research (DVCR) launches new, world-class clinical pharmacology unit and headquarters in Overland Park, Kansas.
Release Versions

Contacts

Zach Bader
Vice President, Business Development
913-333-3000
zbader@drvince.com

Social Media Profiles
More News From Dr. Vince Clinical Research

Dr. Vince Clinical Research Appoints World-Renowned Drug Developer, Clinical Pharmacologist and Neuroscientist Dr. Sheldon Preskorn as Senior VP of Neuroscience

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research (DVCR) today announced the appointment of Sheldon Preskorn, M.D., as its Senior Vice President of Neuroscience....

Dr. Vince Clinical Research Announces First Dosing in a Phase II Study in Patients With Depression

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research announced the first dosing in a Phase II multicenter trial of SPN-820 in adults with major depressive disorder (MDD)....

Dr. Vince Clinical Research Launches New Solution for Organ Impairment Studies

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research (DVCR) announced a new solution that will challenge the current landscape for managing organ impairment studies....
Back to Newsroom